The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
https://pubmed.ncbi.nlm.nih.gov/38758239/
京都大学 島津 裕 Cancer Immunology, Immunotherapy.2024 May 17;73(7):135.
研究発表実績
研究発表実績